Controversies in T1 bladder Ca: Early cystectomy vs. TUR
The management of patients with T1 grade III bladder cancer remains controversial,and experts disagree on the timing of radical cystectomy. In this UrologyTimes point/counterpoint discussion, James Montie, MD, and Michael Droller,MD, debate the merits of early cystectomy versus transurethral resection(TUR) and associated therapy. Dr. Montie is professor of urologic oncologyand chairman, department of urology, University of Michigan, Ann Arbor.Dr. Droller is professor and chairman of the department of urology, MountSinai Medical Center, New York. UT Editorial Consultant Robert C. Flanigan,MD, professor and chairman, department of urology, Loyola University MedicalCenter, Maywood, IL, served as moderator of the discussion.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track Designations for NMIBC
December 5th 2023The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.
